FLT1 and neoplasm: In this context, since D16F7 can interact with VEGFR-1 expressed by tumor cells as well as by endothelial cells, the advantage of D16F7 in the control of GBM growth is two-fold: the mAb may inhibit tumor cell invasion and angiogenesis.